Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

GRI Bio Inc

GRI ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.89

▼ -0.53%

Market Cap $4.13M · Vol 43.20K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.13M

Micro Cap

Div Yield

N/A

EPS Growth

+96.08%

YoY

RSI (14)

51.80

Momentum

Beta

-1.13

vs Market

52W High

$64.12

97.05% below

52W Low

$1.37

37.96% above

Volume

43.20K

Avg 67.79K

P/B

0.57

Price-to-book

ROE

N/A

Return on equity

Free Float

99.63%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, GRI Bio Inc (GRI) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GRI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-34.38%

+13.17%

-16.74%

-25.59%

YTD

-72.65%

-96.27%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,956,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-166.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.57
P/FCF	N/A
EPS Growth	+96.08%
Outstanding Shares	2.19M

Technical Indicators

50-Day SMA	$1.74
200-Day SMA	$5.81
RSI (14)	51.80
Beta	-1.13
52-Week High	$64.12
52-Week Low	$1.37

Volume Today	43.20K
Avg Daily Volume (30D)	67.79K
Relative Volume	0.64x
Volatility (10D)	236.19
Volatility (30D)	178.27
Free Float	99.63%

Analyst Consensus

BUY

Current Price $1.89

Mean Target $153.50

52W Low$1.37 52W High$64.12

Current

Target

$1.37 $64.12

Current Analyst target

+8,021.69% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00XZQMLW5

ISINUS3622AW5029

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG +0.56% ONC BeOne Medicines AG +2.11% 068270.KS Celltrion, Inc. +0.34% ABVX Abivax SA -4.27% ABVX.PA Abivax SA -1.63%

Company Profile

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).